The Study Aims to Measure the Metabolome in Melanoma Patients Using NMR Spectroscopy and Gas Chromatography and to Analyse Differences Depending on the Course of the Disease.

Last updated: January 3, 2025
Sponsor: Technische Universität Dresden
Overall Status: Active - Recruiting

Phase

N/A

Condition

Melanoma

Malignant Melanoma

Treatment

N/A

Clinical Study ID

NCT06765850
Melanomix
  • Ages > 18
  • All Genders

Study Summary

Prospective, single-centre study with the central question of how the metabolome from blood samples, different body fluids and tissues between patients patients with malignant melanoma in different tumour tumour stages and healthy patients and whether this is suitable for early detection of initial diagnosis, recurrence or stage shift at an early stage.

The biosamples are collected in the BioBank Dresden and used for the NMR and LC-MS analyses described here. It is planned to use the biosamples for further analyses.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Current or past history of melanoma

  • Ongoing therapy or tumour aftercare at the Skin Cancer Centre at Dresden UniversityHospital

Exclusion

Exclusion Criteria:

  • Refusal to participate in the study

  • Lack of capacity to consent

Study Design

Total Participants: 3000
Study Start date:
July 04, 2022
Estimated Completion Date:
June 30, 2027

Connect with a study center

  • University Hospital Carl Gustav Carus

    Dresden, Saxony 01307
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.